Form 4 for NVCR NovoCure Ltd
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001645113-23-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-02 | 2023-02-28 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $0.00 | +13.0K | 56.3K | +30% | $0 |
| D | 2023-03-02 | 2023-02-28 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $76.97 | +21.6K | 21.6K | New | +$1.66M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-02-28 | A | A | 12,992 | $0.00 | 56,278 | D | — | — | (F1) Represents restricted share units that are scheduled to vest on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. |
| 2 | Derivative | Options to Buy Ordinary Shares | 2023-02-28 | A | A | 21,607 | $76.97 | 21,607 | D | $76.97 · 2024-02-28 to 2033-02-27 | 21,607 Ordinary Shares | (F2) Options to buy 21,607 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. |